Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses
Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 31% ownership ...
LPL Financial LLC Acquires 16,608 Shares of Invesco BulletShares 2025 Municipal Bond ETF (NASDAQ:BSMP)
LPL Financial LLC lifted its holdings in shares of Invesco BulletShares 2025 Municipal Bond ETF (NASDAQ:BSMP – Free Report) ...
KLP Kapitalforvaltning AS Buys New Stake in Gibraltar Industries, Inc. (NASDAQ:ROCK)
KLP Kapitalforvaltning AS purchased a new stake in Gibraltar Industries, Inc. (NASDAQ:ROCK – Free Report) during the fourth ...
Investing5d
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock
On Monday, H.C. Wainwright reaffirmed a Neutral rating on shares of Inhibikase Therapeutics Inc (NASDAQ:IKT), which currently trades at $2.29 and has seen a significant 76% surge over the past six ...
Investing5d
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock
On Monday, H.C. Wainwright reaffirmed a Neutral rating on shares of Inhibikase Therapeutics Inc (NASDAQ:IKT), which currently trades at $2.29 and has seen a significant 76% surge over the past six ...
pharmaphorum3d
After ph2 win, Cerevance preps pivotal trials of novel Parkinson's drug
Inhibikase Therapeutics is meanwhile running early-stage trials of a c-Abl inhibitor and Denali Therapeutics/Biogen are working on an LRRK2 inhibitor in Parkinson's, both hoping to show that the ...